Stan

So I'll just list out that kind of what's coming to my mind here as everybody's talking.

One is cost.

Just in general about drugs, and I'll back up on this.

Access.

Health insurance, which I can talk about that.

Orphan drugs.

Okay?

In other words, it's one thing, you know, these...

I'll just call them for lack of a better term right now, these fad drugs.

But what about orphan drugs, you know, where people really need them, but their cost is astronomical.

And then the real question underlying all of this is from your perspectives, what does the public need to know?

So let's back up a little bit here.

Let's talk about costs.

I mean, you guys have been in the field, the two of you have been in this field for a while now.

What do you think?

Do you think cost is really kind of a driver for a lot of these, the problems that we're dealing with as it relates to medications?

But let, all right, so I gotta talk about health insurance a little bit here.

So, okay, for those of us who are a little on the older side, we have this open enrollment period, okay, for health insurance, okay?

All right, just stay with me for a second here.

All right, so yesterday, I'm talking to my health insurance agent who helps, you know, to decide which health plan